Rhabdoid Tumor
Information
- Disease name
- Rhabdoid Tumor
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03233204 | Active, not recruiting | Phase 2 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | September 14, 2017 | September 22, 2024 |
| NCT03213665 | Active, not recruiting | Phase 2 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | November 13, 2017 | September 22, 2024 |
| NCT03213678 | Active, not recruiting | Phase 2 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | November 28, 2017 | October 1, 2024 |
| NCT03220035 | Active, not recruiting | Phase 2 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | November 8, 2017 | September 22, 2024 |
| NCT04483778 | Active, not recruiting | Phase 1 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | July 13, 2020 | December 2040 |
| NCT03709680 | Active, not recruiting | Phase 1/Phase 2 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | May 24, 2019 | February 25, 2025 |
| NCT00179803 | Completed | Phase 2 | Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors | March 1998 | September 2009 |
| NCT01331135 | Completed | Phase 1 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | April 2011 | August 9, 2017 |
| NCT01625351 | Completed | Phase 1 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | August 20, 2012 | February 10, 2020 |
| NCT02390843 | Completed | Phase 1 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors | February 2015 | September 22, 2019 |
| NCT04537715 | Completed | Phase 1 | Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | April 23, 2020 | April 3, 2023 |
| NCT03155620 | Recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | July 31, 2017 | September 30, 2027 |
| NCT04897321 | Recruiting | Phase 1 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | July 6, 2022 | March 1, 2027 |
| NCT05286801 | Recruiting | Phase 1/Phase 2 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | November 17, 2022 | September 30, 2025 |
| NCT03618381 | Recruiting | Phase 1 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | June 18, 2019 | June 2040 |
| NCT00898755 | Recruiting | Collecting and Storing Tissue From Young Patients With Cancer | March 5, 2007 | ||
| NCT05985161 | Recruiting | Phase 2 | A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | August 1, 2023 | August 1, 2029 |
| NCT02581384 | Terminated | Phase 1/Phase 2 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | January 2017 | August 2020 |
| NCT04897880 | Terminated | Phase 2 | A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT | January 9, 2019 | December 24, 2021 |
| NCT05952687 | Withdrawn | Phase 1 | Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors | March 2024 | August 2032 |
- OrphaNumber from OrphaNet (Orphanet)
- 69077
- MeSH unique ID (MeSH (Medical Subject Headings))
- D018335